Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European UnionMARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the company has received CE mark approval for the ReWalk 7 Personal Exoskeleton, clearing it for commercial sale in ...

VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report its participation in the NSC Safety Congress & Expo, taking place September 15–17, 2025 in Denver, Colorado. The NSC Safety Congress & Expo is the world’s largest annual event dedicated to workplace safety, health, and environmental professionals and will have thousan ...

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera’s concurrently announced private placement financing. Talphera expec ...

Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for human therapies and IsoPet® for veterinary applications) Advancing Targeted Cancer Therapies The therapeutic ratio is the amount of radiation delivered to a tumor compared to surrounding healthy tissue and is a critical measure of treatment precision. A high therapeutic ratio minimizes collateral damage while ma ...

BELVIDERE, NJ, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced it will showcase its innovative, award-winning Kick. Sports Nutrition line, recently recognized as the 2025 Sports Nutrition Product of the Year by the Mindful Awards, at ECRM’s Vitamin, Weight Management & Sports Nutrition Session, taking p ...

Establishes the official Dogecoin Treasury of the Dogecoin Foundation and its Newly Established Corporate Arm, the House of Doge The transaction consisted of marquee institutional and crypto native investors including, but not limited to, MOZAYYX, Pantera, GSR, FalconX and Borderless OMAHA, Neb., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), today announced the closing of its private investment in public equity (PIPE) financing. The offeri ...

MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF), a public company engaged in functional nutrition and sustainable biofuel innovation, today provided a comprehensive corporate update. UMeWorld operates a dual-growth platform powered by a single proprietary enzymatic technology. This breakthrough process enables the Company to deliver both DAGola™ functional cooking oils, clinically validated to improve metabolic health, and enzymatic biofuels, designed to convert low-cost feedstocks i ...

Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarc ...

CoinShares International Limited (“CoinShares”) Vine Hill Capital Investment Corp., a special purpose acquisition company listed on the Nasdaq Stock Market (“Vine Hill”), and Odysseus Holdings Limited, a newly formed Jersey entity, (“Odysseus Holdings”)1 today jointly announce that CoinShares, Vine Hill and Odysseus Holdings have agreed on a joint merger plan including a court-sanctioned Scheme of Arrangement (as defined below) under Jersey Law between CoinShares and its shareholders (such joint merger plan ...

Core Insights - Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a significant milestone for the company and the endovascular robotics field [3][4] - The company aims to commercialize the LIBERTY System in the U.S. by Q4 2025, targeting an addressable market of approximately 2.5 million peripheral endovascular procedures annually [2][4] - The LIBERTY System demonstrated a 100% success rate in robotic navigation to target and a 92% relative reduction in radiation exposure for physicians during its pivotal study [4] Company Developments - The CEO, Harel Gadot, emphasized that the FDA clearance validates the company's mission to enhance access to advanced robotic technologies and supports cost-effective healthcare [4] - The company has been developing its commercial readiness strategy since Q2 2025, positioning itself to accelerate market entry following FDA clearance [4] - Microbot Medical plans to continue collecting clinical data for the LIBERTY System during its commercial launch [4] Market Positioning - The LIBERTY System is the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures, aiming to transform the field by reducing the need for traditional capital equipment and dedicated infrastructure [3][4] - The remote design of the LIBERTY System is expected to improve ergonomics and reduce physical strain on healthcare providers, potentially enhancing procedure efficiency and lowering costs [4][6] - The company will present its developments at the H.C. Wainwright Annual Investor Conference on September 9, 2025, to engage with investors and stakeholders [5]